Search

Displaying results 3931 - 3940 of 10000 in total
  1. Drug

    Smilagenin

    go.drugbank.com/drugs/DB05450
    Investigational

    Smilagenin is a novel non-peptide, orally bioavailable neurotrophic factor inducer that readily reverses free radical neurotoxicity produced by 1-ethyl-4- phenylpyridium (MPP+) in dopaminergic neurones … P58 is one of a family of phytochemicals isolated from traditional treatments for the elderly that have previously been shown to offer significant benefit in the treatment of senile dementia.

  2. Drug

    Paliroden

    go.drugbank.com/drugs/DB05454
    Investigational

    It is indicated for use in Alzheimer's Disease and Parkinson’s. … Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines.

    Synonyms: 1-(2-(Biphenyl-4-yl)ethyl)-4-(3-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine
  3. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.

  4. Drug

    ISS-1018

    go.drugbank.com/drugs/DB05463
    Investigational

    ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults. … ISS 1018 is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity.

  5. Drug

    R450

    go.drugbank.com/drugs/DB05469
    Experimental

    R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence.

  6. Drug

    WX-UK1

    go.drugbank.com/drugs/DB05476
    Investigational

    WX-UK1 is a 3-amidinophenylalanine-based non-cytotoxic small molecule that belongs to a new class of drugs. … Independent studies show that administration of Wx-UK1 resulted in a decrease of tumor cell invasion, suggesting its efficacy as a an adjuvant antimetastatic therapy of carcinomas.

  7. Drug

    PBI-1402

    go.drugbank.com/drugs/DB05480
    Experimental

    Since it stimulates immune activity, it has been considered as a candidate for cancer treatment as well as anemia. … PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator.

  8. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis.

  9. Drug

    KW-7158

    go.drugbank.com/drugs/DB05498
    Experimental

    KW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity … The therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion

    Categories: Heterocyclic Compounds, 2-Ring
  10. Drug

    AVN-944

    go.drugbank.com/drugs/DB05500
    Investigational

    AVN944 is a biotech drug that demonstrated a statistically meaningful impact on IMPDH and other proteins that are critical to activities in cancer cells, including nucleotide biosynthesis, energy and metabolism … It is being investigated for the treatment of patients with advanced hematologic malignancies.